GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Organovo Holdings Inc.
Organovo, a pioneer in 3D tissue bioprinting, shares reflect a long and arduous history of commercializing a revolutionary technology. The chart tells the story of high hopes followed by scientific and financial difficulties in the quest to create a viable product.
Share prices of companies in the market segment - Pharma metabolism
Organovo Holdings is a pioneer in 3D bioprinting, developing technology to create functional human tissues for medical research. We've categorized it under "Pharma: Metabolism." The chart below shows how investors view the regenerative medicine sector.
Broad Market Index - GURU.Markets
Organovo Holdings is a pioneer in 3D bioprinting, developing technology to create functional human tissues for medical research. We've categorized it under "Pharma: Metabolism." The chart below shows how investors view the regenerative medicine sector.
Change in the price of a company, segment, and market as a whole per day
ONVO - Daily change in the company's share price Organovo Holdings Inc.
For Organovo Holdings, Inc., a pioneer in 3D tissue bioprinting, daily volatility reflects its sensitivity to scientific breakthroughs. This metric is an indicator of progress in commercializing its technology for preclinical studies.
Daily change in the price of a set of shares in a market segment - Pharma metabolism
Organovo Holdings was a pioneer in 3D bioprinting of human tissue for medical research. The company's history reflects the enormous challenges facing the commercialization of revolutionary technologies. The chart below shows the volatility in the biotech sector, illustrating the high risks such companies face.
Daily change in the price of a broad market stock, index - GURU.Markets
Organovo is a pioneer in 3D bioprinting, printing human tissue for research. This revolutionary company's shares reflect the high hopes and risks associated with the future of medicine, and their high volatility impacts the entire market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Organovo Holdings Inc.
For Organovo Holdings, Inc., the year-over-year performance is a story of transformation. Its market cap change over the past 12 months reflects its strategic pivot to developing liver disease treatments after struggling with 3D tissue bioprinting. Its valuation is a bet on success in a new, more traditional pharmaceutical field.
Annual dynamics of market capitalization of the market segment - Pharma metabolism
As a pioneer in 3D bioprinting, Organovo is a bet on the future of medicine. Its performance relative to the sector will reveal how much investors believe in its ability to commercialize its revolutionary, yet still experimental, technology for drug development.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Organovo, a pioneer in 3D bioprinting human tissue for drug testing, aims to transform pharmaceutical research. Its year-over-year market capitalization reflects the long and arduous journey from scientific concept to commercial application.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Organovo Holdings Inc.
Organovo is a pioneer in 3D tissue bioprinting. Its monthly growth reflects progress in its research programs and partnerships with pharmaceutical companies to use its tissues in preclinical studies.
Monthly dynamics of market capitalization of the market segment - Pharma metabolism
Organovo was a pioneer in 3D bioprinting, aiming to create human tissue for medical research and therapeutic applications. The graph below illustrates the overall dynamics in the pharmaceutical and metabolic sectors, reflecting the high risks and long road from breakthrough technology to commercialization.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
3D bioprinting stocks are among the most futuristic and speculative stories on the market. The chart below shows the overall risk appetite. Is Organovo Holdings moving wildly, reacting to the slightest shifts in investor sentiment?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Organovo Holdings Inc.
The weekly performance of Organovo, a pioneer in 3D tissue bioprinting, reflects the long and complex journey from technology to product. Its stock price responds to any progress in using its printed tissues for drug testing and, potentially, transplantation.
Weekly dynamics of market capitalization of the market segment - Pharma metabolism
Organovo Holdings was a pioneer in 3D bioprinting of human tissue for medical research. The chart shows how its weekly performance compares to the biotech sector, reflecting the challenges of commercializing this complex technology and investor confidence in its long-term potential.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Organovo is a pioneer in 3D tissue bioprinting. Being an early-stage company, its shares can be highly volatile. The chart will reveal whether Organovo shares exist in a separate universe, reacting solely to technology news, or whether investors' risk appetite ties them to the market.
Market capitalization of the company, segment and market as a whole
ONVO - Market capitalization of the company Organovo Holdings Inc.
Organovo's market capitalization tells the story of a pioneer in 3D bioprinting of human tissue. Its long decline on the chart is a narrative of how a futuristic technology collided with the harsh reality of a long road to commercialization. Its dynamics reflect the market's assessment of its shift in focus to tissue implant development.
ONVO - Share of the company's market capitalization Organovo Holdings Inc. within the market segment - Pharma metabolism
Organovo was a pioneer in 3D bioprinting of human tissue. Its current share of the sector's market capitalization reflects the shift in focus and challenges faced by the technology. The chart below tells the story of how investor expectations for one of the most futuristic ideas in biotech have evolved.
Market capitalization of the market segment - Pharma metabolism
Organovo is one of the first companies to engage in 3D bioprinting of human tissue. The chart below shows the overall market capitalization of this futuristic sector. Its dynamics reflect both the technology's enormous scientific potential and the challenges of commercializing it and finding a profitable business model.
Market capitalization of all companies included in a broad market index - GURU.Markets
Organovo was a pioneer in 3D bioprinting of human tissue. Its market capitalization tells a story of high hopes and the challenges of implementing futuristic technologies. Its performance on the overall chart is an instructive example of how even the most breakthrough scientific ideas take time to become commercially successful.
Book value capitalization of the company, segment and market as a whole
ONVO - Book value capitalization of the company Organovo Holdings Inc.
Organovo's balance sheet is based on its capital and its unique 3D bioprinting technology for human tissue used in preclinical drug trials. This is a tangible, scientific foundation that could replace animal testing. How has this pioneering, yet troubled, biotech asset evolved? The chart below tells its story.
ONVO - Share of the company's book capitalization Organovo Holdings Inc. within the market segment - Pharma metabolism
Organovo was a pioneer in 3D bioprinting of human tissue, which required unique laboratories and equipment. The chart reflects the share of these cutting-edge biotech assets, demonstrating the physical foundation upon which its ambitious research was built.
Market segment balance sheet capitalization - Pharma metabolism
Organovo, a pioneer in 3D tissue bioprinting, has a capital-intensive R&D business. This requires unique laboratories and equipment. The BCap_Seg chart for the biotech sector shows how expensive it is to develop future technologies in regenerative medicine.
Book value of all companies included in the broad market index - GURU.Markets
Organovo's capital lies not in its drugs, but in its unique 3D bioprinting technology for human tissue for use in preclinical studies. The company's assets are its patents and specialized equipment. The chart below shows the financial weight of this pioneer in the field of regenerative medicine.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Organovo Holdings Inc.
Organovo Holdings is involved in 3D bioprinting of human tissue. Its balance sheet is comprised of unique equipment and patents. Its market capitalization represents a futuristic bet that printed organs will become a reality in medicine. The chart shows how much investors believe in this fantastical, yet potentially revolutionary, technology.
Market to book capitalization ratio in a market segment - Pharma metabolism
Organovo Holdings was a pioneer in 3D tissue bioprinting but has shifted its focus to therapeutic drug development. Its current valuation reflects both the remaining potential of its technologies and significant market skepticism about its new strategy.
Market to book capitalization ratio for the market as a whole
Organovo Holdings, Inc. operates in tissue bioprinting, a knowledge-intensive technology. Its value is determined by its intellectual property, not its production assets. This chart shows how much the market is willing to reward companies for breakthrough but risky technologies compared to average valuations.
Debts of the company, segment and market as a whole
ONVO - Company debts Organovo Holdings Inc.
Organovo, a pioneer in 3D bioprinting of human tissue, uses R&D capital to apply its technology to drug development and disease treatment. This chart shows how the company funds its long-term, high-risk research, which has the potential to revolutionize regenerative medicine.
Market segment debts - Pharma metabolism
Organovo Holdings was a pioneer in 3D bioprinting of human tissue, but it ran into difficulties. The company has now shifted focus. This chart reflects its complex financial history and shows how it is managing its legacy and funding its new strategy after the failure of its initial ambitious technology.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Organovo Holdings Inc.
Organovo Holdings was a pioneer in 3D bioprinting of human tissue, but it has faced challenges. This chart reflects its financial position. It helps understand how debt, possibly accumulated during periods of active research, impacts its ability to restructure or find new applications for its technologies.
Market segment debt to market segment book capitalization - Pharma metabolism
Organovo was a pioneer in 3D bioprinting of human tissue, but faced challenges commercializing the technology. The company is now focused on drug development. The chart shows debt trends in the biotech sector, illustrating the enormous investments required to bring such complex technologies to market.
Debt to book value of all companies in the market
Organovo Holdings, Inc., a pioneer in 3D tissue bioprinting, requires significant investment in breakthrough but not yet fully commercialized technologies. This chart shows the overall debt burden in the market. It allows one to assess the riskiness of the company's financial model and how it raises capital to fund its unique R&D projects.
P/E of the company, segment and market as a whole
P/E - Organovo Holdings Inc.
Organovo Holdings pioneered 3D bioprinting of human tissue for medical research and drug development. This chart shows how the market is evaluating its complex journey. The dynamics reflect the challenges of commercializing this cutting-edge technology and the company's ongoing search for a sustainable business model.
P/E of the market segment - Pharma metabolism
This industry chart for biotech companies serves as a benchmark for Organovo. It reflects general speculative valuations in the sector. Comparisons with it help understand how the market views Organovo's unique technology for 3D bioprinting human tissue and whether it believes in its long-term potential for disease modeling and drug development.
P/E of the market as a whole
Organovo is a pioneer in 3D bioprinting human tissue for use in drug development. Its valuation is a pure bet on this futuristic technology. It is not tied to the general economic cycles reflected here, but depends on the success of its developments and partnerships with pharmaceutical companies.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Organovo Holdings Inc.
The chart from Organovo Holdings, Inc., a company engaged in 3D bioprinting of human tissue, shows market expectations for the commercialization of its technology. It reflects investors' belief that its developments will be in demand for drug testing and, potentially, regenerative medicine.
%20P%2FE%20Organovo%20Holdings%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Organovo-Holdings-Inc.&v=1772657501680 "Chart of the company's future (projected) P/E Organovo Holdings Inc.")
Future (projected) P/E of the market segment - Pharma metabolism
Organovo Holdings is a pioneer in 3D bioprinting, developing technologies for creating functional human tissues. The company initially focused on creating tissues for transplantation, but has now shifted its focus to using them for preclinical drug trials. The chart shows forecasts for the biotech sector, helping to assess the market's confidence in Organovo's current business model.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-metabolism&v=1772657501695 "Future (projected) P/E graph of the market segment - Pharma metabolism")
Future (projected) P/E of the market as a whole
Organovo Holdings, Inc. is a pioneer in 3D bioprinting of human tissue. This technology has enormous potential in drug development and regenerative medicine. The company's valuation is a long-term bet. This chart shows how willing investors are to fund fundamental scientific research with a very long time horizon.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772657501720 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Organovo Holdings Inc.
Organovo Holdings was a pioneer in 3D bioprinting human tissue for medical research. The company faced challenges in commercialization. This timeline reflects the company's history as it attempted to turn its revolutionary technology into a profitable business, but faced scientific and financial challenges.
Profit of companies in the market segment - Pharma metabolism
Organovo Holdings was a pioneer in 3D bioprinting of human tissue for medical research. This graph, which reflects profitability in the pharmaceutical sector, demonstrates the complex path from innovation to commercial success. The company has encountered difficulties monetizing its unique technology and is now exploring new strategic directions for its development.
Overall market profit
Organovo Holdings is a pioneer in 3D bioprinting of human tissue. This technology has enormous potential in drug testing and regenerative medicine. The company's success depends on the commercialization of this complex technology. Economic growth, reflected in this chart, is driving investment in breakthrough scientific platforms that could transform the future of medicine.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Organovo Holdings Inc.
Organovo Holdings pioneered 3D bioprinting of human tissue for medical research and drug development. The company has now shifted its focus to developing therapies for liver disease. This chart reflects analysts' speculative expectations for the success of its new strategy and clinical programs.
%20profit%20of%20the%20company%20Organovo%20Holdings%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Organovo-Holdings-Inc.&v=1772657501754 "Graph of future (projected) profit of the company Organovo Holdings Inc.")
Future (predicted) profit of companies in the market segment - Pharma metabolism
Organovo Holdings was a pioneer in 3D bioprinting of human tissue for medical research and drug development. The company is undergoing a transformation and searching for a new strategy. Assessing its prospects requires analyzing this new direction. This chart for the biotech sector provides only a general overview; the key decisions are the company's internal ones.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-metabolism&v=1772657501760 "Graph of future (predicted) profits of companies in a market segment - Pharma metabolism")
Future (predicted) profit of the market as a whole
Organovo Holdings develops 3D bioprinting technology for human tissue for medical research. It's an innovative business. The overall economic forecast, reflected in this chart, influences the R&D budgets of major pharmaceutical companies—its potential clients and partners.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772657501797 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Organovo Holdings Inc.
Organovo Holdings was a pioneer in 3D bioprinting of human tissue for medical research and drug development. The chart shows how the market values its research revenue. It reflects confidence in the long-term potential of this technology, which could revolutionize drug testing and regenerative medicine.
P/S market segment - Pharma metabolism
Organovo Holdings pioneered 3D bioprinting of human tissue for medical research and drug development. The company is undergoing transformation. This chart, which displays average valuations in the sector, helps understand how the market values companies operating at the intersection of biotech and engineering, and how it views Organovo's future prospects.
P/S of the market as a whole
Organovo is a pioneer in 3D bioprinting human tissue for use in medical research and drug development. This chart, which reflects revenue estimates for traditional companies, highlights that Organovo's valuation is based on a long-term vision of a future where bioprinting can revolutionize medicine.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Organovo Holdings Inc.
Organovo is a pioneering 3D bioprinting company, aiming to create human tissue for use in medical research and, potentially, transplantation. This chart reflects investors' faith in the long-term, almost fantastical, potential of this technology, although commercialization is still a long way off.
%20P%2FS%20Organovo%20Holdings%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Organovo-Holdings-Inc.&v=1772657501889 "The graph of the company's future (projected) P/S Organovo Holdings Inc.")
Future (projected) P/S of the market segment - Pharma metabolism
Organovo Holdings, Inc. is a pioneer in 3D bioprinting, developing functional human tissues for use in medical research and therapeutic applications. This chart shows the average estimated future sales in the biotech sector. It helps understand how highly the market values Organovo's technology for transforming drug development.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-metabolism&v=1772657501912 "Future (projected) P/S market segment graph - Pharma metabolism")
Future (projected) P/S of the market as a whole
Organovo Holdings is a pioneer in 3D bioprinting, developing technology to create living human tissue for medical research. This chart reflects market expectations for future revenue overall. The company's technologies have the potential to revolutionize drug development, making it faster and cheaper, a key goal for the entire pharmaceutical industry.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772657501935 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Organovo Holdings Inc.
This chart shows the revenue of Organovo Holdings, a biotech company previously known for its developments in 3D bioprinting of human tissue for research. The company is now focused on developing therapeutic solutions. Its revenue at this stage may be minimal and tied to research contracts.
Sales of companies in the market segment - Pharma metabolism
Organovo Holdings is a pioneer in 3D bioprinting, developing technology to create functional human tissues for medical research and therapeutic applications. This graph illustrates the emerging regenerative medicine market. Organovo's technologies have the potential to revolutionize drug development and, in the future, become a source of tissue for transplantation.
Overall market sales
Organovo Holdings specializes in 3D bioprinting of human tissue for medical research. Demand for its technology comes from pharmaceutical companies. This total revenue chart reflects the state of the R&D sector, which, during periods of growth, invests more actively in innovative drug development tools.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Organovo Holdings Inc.
Organovo is a cutting-edge biotechnology company developing 3D bioprinting technology for functional human tissues. Future revenue depends on the application of this technology in drug development. The chart reflects long-term expectations for the tissue engineering market.
%20sales%20of%20the%20company%20Organovo%20Holdings%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Organovo-Holdings-Inc.&v=1772657502000 "Schedule of future (projected) sales of the company Organovo Holdings Inc.")
Future (projected) sales of companies in the market segment - Pharma metabolism
Organovo Holdings pioneered the 3D bioprinting of human tissue for use in medical research and drug development. The company is undergoing a transformation, focusing on therapeutic applications. This chart shows the forecast for the entire pharmaceutical market, where tissue engineering technologies can accelerate drug discovery.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-metabolism&v=1772657502032 "Schedule of future (projected) sales of companies in the market segment - Pharma metabolism")
Future (projected) sales of the market as a whole
Organovo Holdings was a pioneer in 3D bioprinting of human tissue for medical research, but has now shifted its focus to therapeutic drug development. This schedule, reflecting the investment climate in biotech, impacts the company's ability to finance its new strategic course and costly clinical trials.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772657502136 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Organovo Holdings Inc.
Organovo was a pioneer in 3D bioprinting human tissue for medical research and drug development. Its financial performance reflects the enormous investment in developing and refining this cutting-edge technology. This chart illustrates the challenges associated with commercializing a breakthrough but capital-intensive scientific platform and its long road to profitability.
Market segment marginality - Pharma metabolism
Organovo pioneered the 3D bioprinting of human tissue for medical research and drug development. Profitability in this revolutionary but complex field has proven elusive. This chart reflects the significant investment and operational challenges faced by companies at the forefront of biotechnology when attempting to commercialize breakthrough technologies.
Market marginality as a whole
Organovo is a pioneer in 3D bioprinting, a technology that enables the creation of functional human tissue in the lab. These tissues are used for drug testing and research. Against this backdrop, reflecting the current economic climate, Organovo is betting on the future of medicine. Their success depends on pharmaceutical companies adopting their technology to accelerate R&D.
Employees in the company, segment and market as a whole
Number of employees in the company Organovo Holdings Inc.
Organovo is a pioneer in 3D bioprinting human tissue for use in medical research. Its team consists of bioengineers and scientists. This graph reflects the intensity of its research and development efforts and the commercialization of this futuristic technology.
Share of the company's employees Organovo Holdings Inc. within the market segment - Pharma metabolism
Organovo Holdings is at the forefront of biotechnology, leveraging its platform for 3D bioprinting human tissue. This chart shows the company's unique talent pool in this futuristic field. It reflects its scientific potential for creating tissue models for developing and testing new drugs.
Number of employees in the market segment - Pharma metabolism
Organovo Holdings, Inc. is a pioneer in 3D bioprinting, creating functional human tissues for medical research and therapeutic applications. This chart reflects employment trends in regenerative medicine. The growing number of bioengineers and scientists here indicates progress in creating complex tissue models that could accelerate drug development and eventually replace organ transplants.
Number of employees in the market as a whole
Organovo Holdings is developing 3D bioprinting technology for human tissue for medical research. Demand for its technology comes from pharmaceutical companies. Overall economic growth, reflected in this chart, supports stable R&D budgets in the pharmaceutical industry, allowing companies to invest in innovative drug testing methods.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Organovo Holdings Inc. (ONVO)
Organovo Holdings was a pioneer in 3D bioprinting of human tissue but later shifted focus. In a business based on deep R&D, like bioprinting, this chart shows how much the market values the technology. A high cost per employee suggests that the value lies in patents and know-how, not production capacity. The chart's trajectory may also reflect a loss of market confidence in the technology.
%20of%20the%20company%20Organovo%20Holdings%20Inc.%20(ONVO)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Organovo-Holdings-Inc.-ONVO&v=1772657502406 "Chart of market capitalization per employee (in thousands of dollars) of the company Organovo Holdings Inc. (ONVO)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma metabolism
Organovo was a pioneer in 3D bioprinting of human tissue for medical research and drug development. The company's value is based on the potential of its unique technology. This chart reflects how investors value its intellectual property and the long-term prospects for applying this cutting-edge technology in medicine.
%20by%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-metabolism&v=1772657502426 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma metabolism")
Market capitalization per employee (in thousands of dollars) for the overall market
Organovo Holdings was a pioneer in 3D bioprinting of human tissue for medical research. The chart reflects the valuation of this breakthrough, yet challenging, technology. It shows how investors assess the technology's long-term potential, even if the path to profitability proves challenging.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772657502448 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Organovo Holdings Inc. (ONVO)
Organovo was a pioneer in 3D bioprinting human tissue for use in drug research. However, the company has encountered challenges. This graph likely reflects very high R&D costs per employee with no significant revenue, reflecting the difficulty of commercializing this futuristic technology.
%20Chart%20Organovo%20Holdings%20Inc.%20(ONVO)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Organovo-Holdings-Inc.-ONVO&v=1772657502461 "Company Profit Per Employee (in thousands of dollars) Chart Organovo Holdings Inc. (ONVO)")
Profit per employee (in thousands of dollars) in the market segment - Pharma metabolism
Organovo is a pioneer in 3D bioprinting, creating human tissue in the lab for drug testing. It provides R&D services to pharmaceutical companies. This metric (loss per employee) reflects the high cost of research and development of this unique technology.
%20in%20the%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-metabolism&v=1772657502464 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma metabolism")
Profit per employee (in thousands of dollars) for the market as a whole
Organovo Holdings is a biotech company that historically focused on 3D tissue bioprinting (for R&D). After a failure, they focused on developing liver therapeutics. This is an R&D business. This chart shows the capital burn rate: the operating loss per research team.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772657502476 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Organovo Holdings Inc. (ONVO)
Organovo Holdings is a pioneer in 3D bioprinting, creating functional human tissues for medical research. This chart reflects the early stages of commercialization of its unique technology. Growing revenue per employee reflects contracts with pharmaceutical companies that use its tissues for drug testing.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Organovo-Holdings-Inc.-ONVO&v=1772657502485 "Sales chart per company employee Organovo Holdings Inc. (ONVO)")
Sales per employee in the market segment - Pharma metabolism
Organovo is a pioneer in 3D bioprinting. They aim to create functional human tissues (such as liver) for drug testing and, potentially, transplantation. This graph shows the revenue (from R&D services) generated by each employee (bioengineer, scientist). This measures the productivity of their futuristic technology.
Sales per employee for the market as a whole
Organovo (ONVO) is a pioneer in 3D bioprinting of human tissue. After shifting its focus, the company is developing these tissues for therapeutic applications (liver disease treatment). The company is in the R&D stage. This chart illustrates the R&D situation: the company has no commercial revenue, and its research staff is working on creating an innovative product.
Short shares by company, segment and market as a whole
Shares shorted by company Organovo Holdings Inc. (ONVO)
For years, Organovo Holdings has been promising a revolution with 3D bioprinting of human tissue. This chart shows bearish sentiment. Investors shorting the stock are apparently tired of waiting and are betting that this technology will remain science fiction and never yield a commercial product.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Organovo-Holdings-Inc.-ONVO&v=1772657502521 "Short Shares Chart for the Company Organovo Holdings Inc. (ONVO)")
Shares shorted by market segment - Pharma metabolism
Organovo Holdings is at the forefront of biotechnology, specializing in 3D bioprinting of functional human tissue. This chart shows the total short position volume across the entire regenerative medicine sector. It highlights the market's skepticism regarding the commercialization timeline and regulatory challenges facing this futuristic industry.
Shares shorted by the overall market
Organovo (ONVO) is a pioneer in 3D fabric printing. It's one of the most futuristic and speculative stories around. When this general fear indicator rises, investors panic and flee from this "science fiction." Unwilling to wait 10-15 years, they sell ONVO shares to cash out.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Organovo Holdings Inc. (ONVO)
This oscillator for Organovo is a story of faded hope in 3D organ printing. The company was a pioneer in tissue bioprinting (liver). The stock was overheated (above 70) many years ago. The lack of a commercial product, a clinical failure, and high cash burn keep the stock deeply oversold (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Organovo-Holdings-Inc.-ONVO&v=1772657502544 "RSI 14 indicator chart for the company's stock Organovo Holdings Inc. (ONVO)")
RSI 14 Market Segment - Pharma metabolism
Organovo (ONVO) is a pioneer in 3D bioprinting. They literally "print" human tissue (such as liver) for use in preclinical studies. This is highly speculative science. This chart tracks the overall sentiment in the Pharma/Metabolism sector. It helps investors understand whether ONVO's performance reflects their technology or whether the entire industry is overheated.
RSI 14 for the overall market
For Organovo, a biotech company, this graph is a lifeline. Its survival depends on funding R&D. During periods of market euphoria, investors are willing to generously fund risky but promising research. During periods of panic, the money supply is turned off, and cash-burning companies risk running out of funds.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ONVO (Organovo Holdings Inc.)
Organovo (ONVO) is a pioneer in 3D bioprinting, specializing in the printing of functional human tissues (such as liver) for pharmaceutical R&D. This chart shows the average target price. It reflects analysts' speculative assessment of the company's ability to commercialize these tissues (for drug testing) and its long-term potential.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ONVO-Organovo-Holdings-Inc.&v=1772657502598 "A chart showing analyst consensus forecasts for the expected stock price. ONVO (Organovo Holdings Inc.)")
The difference between the consensus estimate and the actual stock price ONVO (Organovo Holdings Inc.)
Organovo (ONVO) is a pioneer in 3D bioprinting. The company was one of the first to "print" living human tissue (liver) for R&D. This chart shows how far the current share price differs from its "fair" value. It reflects analysts' views on their challenging comeback and the value of their R&D technology.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ONVO-Organovo-Holdings-Inc.&v=1772657502608 "A chart showing the difference between the consensus forecast and the actual stock price. ONVO (Organovo Holdings Inc.)")
Analyst consensus forecast for stock prices by market segment - Pharma metabolism
Organovo, a pioneer in 3D bioprinting, has focused on R&D for liver disease treatments after its failure with organ printing. This chart reflects analysts' overall expectations for the entire metabolic pharma sector. It shows whether experts believe this risky R&D transformation will succeed.
Analysts' consensus forecast for the overall market share price
Organovo (ONVO) is a pioneer in bioprinting. They've been trying to 3D print human tissue (liver) for R&D and, potentially, transplantation. This is futuristic science. This chart shows the overall risk appetite. It reflects the market's willingness to fund breakthrough, but extremely expensive, R&D projects. (Note: VIVS also cites Organovo.)
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Organovo Holdings Inc.
Organovo (ONVO) is a pioneer that fell. They were leaders in 3D bioprinting (printing living human tissue, such as the liver, for R&D). This chart is a summary indicator of their battle for survival. It reflects their (almost complete) destruction of their business and their desperate attempts to reboot and find a new, viable business model.
AKIMA Market Segment Index - Pharma metabolism
Organovo (ONVO) is a pharma-metabolism and 3D printing company. Rather than offering treatments, they 3D print living human tissue (liver) so pharmaceutical companies can test drugs on it. This chart compares their composite index to the sector, showing how their 3D printing technology outperforms the competition.
The AKIM Index for the overall market
Organovo Holdings is a pioneer in 3D bioprinting of human tissues for research and therapy (intestines, liver). This chart, reflecting the market average, provides context. It helps assess how this scientific platform, which is seeking application in drug development, compares to overall macroeconomic trends.
